Viral Vector API Characterization of Product-Related Impurities
FDA’s final CMC guidance sets expectations for manufacturing and quality for human gene therapy INDs. This article reviews existing analytical applications, focusing on viral vector characterization of impurities.
In January 2020, the FDA issued Final Guidance for Industry: Chemistry Manufacturing and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs) and other guidance documents for human gene therapies, which set expectations for manufacturing and demonstration of quality (1). These products are applied to deliver genetic material (transgenes) or modified cells that have been designed to alleviate or even eliminate a broad range of diseases that are rooted in the genetics of individuals or populations of patients.
Read this article in BioPharm International’s Regulatory Sourcebook October 2020 eBook.
Article Details
BioPharm International
eBook: Regulatory Sourcebook, October 2020
October 2020
Pages: 12–17
Citation
When referring to this article, please cite it as P. Wunderli et al.,“Viral Vector API Characterization of Product-Related Impurities," BioPharm International Regulatory Sourcebook eBook (October 2020).
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
